Current pharmacologic testing for horner syndrome

Abstract

First described in 1727, Horner syndrome occurs from injury to one of the three neurons in the oculosympathetic pathway. Its presence can be confirmed with pharmacologic testing, traditionally including cocaine testing with hydroxyamphetamine localization. More recently, apraclonidine testing has become a viable alternative in some practices. Concern has been raised regarding the possibility of false-negative results with apraclonidine testing as well as the safety of its use in young children.

Lateral Tortikolis: Horner Sendromu ile Komplike Olan Bir Olgu Sunumu

“…In our case, pupil dilatation associated with super sensitivity was observed in testing with apraclonidine and, anisocoria reversed as expected (9,10). Neurological examination of the patient was normal except for partial HS signs.…”

Inhibition by ketamine and amphetamine analogs of the neurogenic nitrergic vasodilations in porcine basilar arteries

“…2 and 5), possessed rather weak effects on blocking nicotine-induced inward currents in the SCG neurons and α3β2-nAChRs expressing Xenopus oocytes, and calcium influx into the SCG neurons. This may justify its safety in clinical practice (Mughal and Longmuir, 2009). …”

The hazards of being a gentleman farmer: a case of transient Horner's syndrome

“…However, this test does not establish the cause for the Horner's syndrome and hence was not utilized in our patient. 8 …”